Bruker Corporation has acquired MOLECUBES NV to strengthen its portfolio in preclinical nuclear molecular imaging, enhancing its capabilities and market presence.

Target Information

Bruker Corporation (Nasdaq: BRKR) has successfully acquired MOLECUBES NV, a pioneering firm specializing in benchtop nuclear molecular imaging (NMI) systems for preclinical applications. Founded in 2015 in Ghent, Belgium, MOLECUBES has established itself as a key player in this niche market, developing and selling advanced PET, SPECT, and CT CUBES™ systems. With over 70 installations across prominent research institutions and biopharma companies, MOLECUBES aims to provide innovative solutions that uphold rigorous standards of image quality while maintaining a compact laboratory footprint.

Under this acquisition, MOLECUBES will continue to operate with its established team, focusing on innovation and agility within the Bruker BioSpin Preclinical Imaging Division. The merger opens the door for enhanced collaboration between the R&D and application teams of both entities, which is expected to drive advancements in NMI technologies and broaden the scope of preclinical research methods.

Industry Overview in Belgium

Belgium possesses a robust life sciences sector, with a strong emphasis on biotechnology and pharmaceuticals. The country is home to numerous innovative startups and established companies that work on cutting-edge technologies aimed at